ArunA Biomedical to commercialize human embryonic stem cell derived mesenchymal cells

Mar 29 2009

ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.

Derived from pluripotent human embryonic stem cells, ArunA's hMC lines will offer unique, highly proliferative uniform populations of mesenchymal cells in a feeder free monolayer culture.

The introduction of our CELL-EZ hMC cell lines is a significant step forward for stem cell research." Dr. Steven Stice, ArunA CSO and Co-Founder commented, "CELL-EZ hMC will provide a human cell based format for a wide range of research in areas from osteogenisis to cancer research. Unlike human bone marrow and other tissue derived mesenchymal cells, ArunA's hMC cells have the unique ability to differentiate into osteoblasts and chondrocytes but not adipocytes, making them a unique tool for research and drug discovery directed at areas such as Osteoporosis."

The CELL-EZ hMC cell lines were further developed by ArunA through a technology license agreement with the University of Georgia using a proprietary platform technology for producing progenitor cells from pluripotent stem cells. The CELL-EZ hMC cell lines are from a stable genetic background and can be genetically modified to produce constant and more informative research results. This product line compliments ArunA's portfolio of pluripotent stem cell products derived from human embryonic stem cells.